Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 1 7Phase 3 3Phase NA 2Phase EARLY_PHASE1 2Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroendocrine Tumors 2Pheochromocytoma 1Paraganglioma 1Neuroblastoma 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Temozolomide 10Irinotecan 8Cyclophosphamide 7dinutuximab 5aldesleukin 4Interleukin-2 4Granulocyte-Macrophage Colony-Stimulating Factor 4sargramostim 3fludarabine 3Topotecan 3Melphalan 3Isotretinoin 3Filgrastim 3gallium Ga 68 dotatate 2Vincristine 2TPI-287 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Magnetic Resonance Spectroscopy 2Carboplatin 2venetoclax 1trametinib 1thymoglobulin 1talazoparib 1sonidegib 1silmitasertib 1plerixafor 1olaparib 1naxitamab 1lutetium Lu 177 dotatate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neuroblastoma × 3-Iodobenzylguanidine × Clear all
NCT00798148 2012-06-04

131I-MIBG With Myeloablative Chemotherapy and Autologous Stem Cell Transplantation for the Treatment of High-risk Neuroblastoma

Tehran University of Medical Sciences

Phase 1/2 Unknown
10 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡